- Home
- SCOR vs EQ Comparison
SCOR vs EQ Comparison
Compare SCOR & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCOR
- EQ
- Stock Information
- Founded
- SCOR 1999
- EQ 2017
- Country
- SCOR United States
- EQ United States
- Employees
- SCOR N/A
- EQ N/A
- Industry
- SCOR Business Services
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- SCOR Consumer Discretionary
- EQ Health Care
- Exchange
- SCOR Nasdaq
- EQ Nasdaq
- Market Cap
- SCOR 29.0M
- EQ 31.1M
- IPO Year
- SCOR 2007
- EQ 2018
- Fundamental
- Price
- SCOR $6.06
- EQ $0.77
- Analyst Decision
- SCOR Buy
- EQ Buy
- Analyst Count
- SCOR 3
- EQ 2
- Target Price
- SCOR $12.83
- EQ $5.00
- AVG Volume (30 Days)
- SCOR 20.4K
- EQ 102.6K
- Earning Date
- SCOR 03-04-2025
- EQ 05-08-2025
- Dividend Yield
- SCOR N/A
- EQ N/A
- EPS Growth
- SCOR N/A
- EQ N/A
- EPS
- SCOR N/A
- EQ N/A
- Revenue
- SCOR $356,047,000.00
- EQ $45,914,000.00
- Revenue This Year
- SCOR $4.01
- EQ $4.77
- Revenue Next Year
- SCOR $4.03
- EQ N/A
- P/E Ratio
- SCOR N/A
- EQ N/A
- Revenue Growth
- SCOR N/A
- EQ 7.70
- 52 Week Low
- SCOR $4.89
- EQ $0.49
- 52 Week High
- SCOR $16.60
- EQ $2.99
- Technical
- Relative Strength Index (RSI)
- SCOR 42.64
- EQ 46.90
- Support Level
- SCOR $5.55
- EQ $0.68
- Resistance Level
- SCOR $7.33
- EQ $0.87
- Average True Range (ATR)
- SCOR 0.56
- EQ 0.08
- MACD
- SCOR -0.06
- EQ -0.01
- Stochastic Oscillator
- SCOR 19.23
- EQ 37.50
About SCOR comScore Inc.
comScore Inc is a United States-based information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. The platforms measure include televisions, mobile devices, computers, tablets, CTV devices and movie theaters. The company generates almost all its revenue from the United States, followed by Europe, Latin America, Canada and Others. It provides solutions for Automotive, Digital Media, Financial Services, FMCG, Pharmaceutical , Retail, Technology and Travel.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.